50% of mice in the BMA-OVA + anti-Gr1 Ab treatment group completely rejected their primary tumors and 3LL-OVA tumor cells (2×105) on re-challenge.
收藏数据链接：
官方服务：
资源简介：
50% of mice in the BMA-OVA + anti-Gr1 Ab treatment group completely rejected their primary tumors and 3LL-OVA tumor cells (2×105) on re-challenge.
创建时间：
2015-12-02
